LUCIUS 卢修斯 特泊替尼 Tepotinib非小细胞肺癌

特泊替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Tepotinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:
cach Tilm-coated tablet contains Tepotimib

LUCiUS

非小细胞肺癌

hydrochloride hydrate 250mg equrvalent to

PHARMACEUTICALS

Indication:
LuciTepo is a kinase inhibitor indicated for the
treatment of adult patients with metastatic non-sma
cel lung cancer (NSCLC) harboring mesenchyma
epithelial transition (MET) exon 14 skipping
alterations

LuciTepo

ns irndicalnon is approv ed under accelerated approva
caseu oi ovcrait response rale and duration ol
response. Continued approval for this indication ma
clinical benefit in confirmatory triale

Tepotinib Tablets

FDA批准

ents for treatient with Lucnlepo on the
Presence of METex14 skipping.
*Kecommended dosage: 450mg orally once daily
with food until disease progression or unacceptaole

225mg

toxicity.
Storage: in a dry place and store at 20C to 25C
Warning:
Keep imedicine out of reach of Children.Do no
administer Luci Tepo durina Preanancy and Lactatio
PLEASESEE PACKAGE INSERT
Manufactured and Marketed by:
LUCIUIS

权威认证

Thongmang village. Xaythany distriet, Vientian

www.Jucius.

warning: to be sold by retail on prescription
of registered nhucieians.o

Rx Only

Dy the phusieresas direct

60 Tablets

口碑质量

适应症:
适用于治疗具有间质-上皮转移(MET)外显子14突
变的转移性非小细胞肺癌(NSCLC)成年患者。
推荐剂量:
每日口服一次,每次450mg,随餐服用,直至疾病
进展或出现不可接受的毒性。